New diabetes drug shows promise in blood sugar control for chinese patients
NCT ID NCT06881264
First seen Jan 29, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tested a new medication called HR17031 against a standard insulin (insulin glargine) in 401 Chinese adults with type 2 diabetes whose blood sugar was not well controlled with oral medications. The main goal was to see if HR17031 could lower blood sugar levels (measured by HbA1c) more effectively over 26 weeks. Participants were adults aged 18-75 with a BMI between 20 and 40, and they continued taking metformin with or without another oral diabetes drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETIC DRUGS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.